Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Hospitalier Universitaire, Amiens
With
cimiez hospital Nice
Institut Bergonié
groupe hospitalier public sud de l'oise
Henri Mondor University Hospital
Centre Henri Becquerel
Hôpital Charles Foix
Saint-Louis Hospital, Paris, France
Age
75–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 75 years old
Histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO classification 2008) including all clinical subtypes (primary mediastinal, intravascular, etc...), with all aaIPI. May also be included : transformed DLBCL from low grade lymphoma (Follicular, other...) and DLBCL associated with some small cell Infiltration in bone marrow or lymph node or CD20+ B-cell lymphoma, with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma or CD20+ Follicular lymphoma grade 3B or CD20+ Aggressive B-cell lymphoma unclassifiable
Relapse ≥ 6 months
ADL ≥ 2
Negative HIV, HBV (anti-HBc negativity) and HCV serologies test within 4 weeks before inclusion
Patient able to give his consent and having signed a written informed consent
Registration in a national health-care system
You may not be if
Central nervous system or meningeal involvement by lymphoma
Poor renal function (creatinine clearance \< 30 ml/min, according to MDRD formula)
Poor hepatic function (total bilirubin level\>30mmol/l, transaminases \>2.5 maximum normal level) unless these abnormalities are related to the lymphoma
Neuropathy grade \> 1
Poor bone marrow reserve as defined by neutrophils\<1.5 G/l or platelets\<100 G/l, unless related to bone marrow infiltration
Other concomitant or previous malignancy, except adequately treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of the skin, or cancer in complete remission for \<5 years
Other serious and uncontrolled non-malignant disease.
Insufficient proficiency of the French language and disability to complete a questionnaire
Patient under guardianship
Clareo Health | Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
